Scolaris Content Display Scolaris Content Display

Radical multimodality therapy for malignant pleural mesothelioma

Esta versión no es la más reciente

Referencias

Additional references

Abdel‐Rahman 2015

Abdel‐Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first‐line therapy: a systematic review. Expert Review of Respiratory Medicine 2015;9(5):533‐49.

Abdel‐Rahman 2017

Abdel‐Rahman O. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma: A propensity score matching of the SEER database. Strahlentherapie und Onkologie 2017 Jan 2 [Epub ahead of print]. [DOI: 10.1007/s00066‐016‐1092‐7]

Algranti 2015

Algranti E, Saito CA, Carneiro AP, Moreira B, Mendonca EM, Bussacos MA. The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil. Cancer Epidemiology 2015;39(5):687‐92.

Allen 2006

Allen A M, Czerminska M, Janne P A, Sugarbaker D J, Bueno R, Harris J R, et al. Fatal pneumonitis associated with intensity‐modulated radiation therapy for mesothelioma. International Journal of Radiation, Oncology, Biology and Physics 2006;65(3):640‐5.

Armato 2013

Armato SG, Labby ZE, Coolen J, Klabatsa A, Feigen M, Persigehl T, et al. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2013;82(2):190‐6.

Baas 2015

Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2015;26(Suppl 5):v31‐9.

Bertoglio 2016

Bertoglio P, Waller DA. The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence. Expert Review of Respiratory Medicine 2016;10(6):663‐72.

Bianchi 2007

Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Industrial Health 2007;45(3):379‐87.

Bridda 2007

Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. Medscape General Medicine 2007;9(2):32.

Brčić 2014

Brčić L, Jakopović M, Brčić I, Klarić V, Milošević M, Sepac A, et al. Reproducibility of histological subtyping of malignant pleural mesothelioma. Virchows Archives 2014;465(6):679‐85.

Calabro 2013

Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy‐resistant advanced malignant mesothelioma: an open‐label, single‐arm, phase 2 trial. Lancet Oncology 2013;14(11):1104‐11.

Calabro 2015

Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy‐resistant malignant mesothelioma: an open‐label, single‐arm, phase 2 study. Lancet Respiratory Medicine 2015;3(4):301‐9.

Chapman 2006

Chapman E, García Diéguez M. Radiotherapy for malignant pleural mesothelioma. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD003880.pub4]

CTCAE 2009

US Department of Health and Human Services. Common terminology criteria of adverse events (CTCAE). Version 4.03. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf Accessed prior to 27 February 2017.

De Perrot 2016

De Perrot M, Feld R, Leighl NB, Hope A, Waddell TK, Keshavjee S, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery 2016;151(2):468‐73.

Egger 1997

Egger M, Smith GD, Phillips AN. Meta‐analysis: principles and procedures. British Medical Journal 1997;315(7121):1533‐7.

Friedberg 2012

Friedberg JS. Photodynamic therapy for malignant pleural mesothelioma. Journal of the National Cancer Institute 2012;10(Suppl 2):S75‐9.

Friedberg 2017

Friedberg JS, Simone CB, Culligan MJ, Barsky AR, Doucette A, McNulty S, et al. Extended pleurectomy‐decortication–based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Annals of Thoracic Surgery 2017;103(3):912‐9.

Galateau‐Salle 2016

Galateau‐Salle F, Churg A, Roggli V, Travis WD. World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 classification. Journal of Thoracic Oncology 2016;11(2):142‐54.

GRADEpro GDT 2014 [Computer program]

GRADE Working Group, McMaster University. GRADEpro GDT. Version Accessed prior to 27 February 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.

Heelan 1999

Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. American Journal of Roentgenology 1999;172(4):1039‐47.

Higgins 2002

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.Available from www.cochrane‐handbook.org, [updated March 2011].

Kadota 2011

Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. Journal of Thoracic Oncology 2011;6(5):896‐904.

Macaskill 2001

Macaskill P, Walter S D, Irwig L. A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine 2001;20:641‐54.

Macleod 2014

Macleod N, Price A, O'Rourke N, Fallon M, Laird B. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer 2014;83(2):133‐8.

MacLeod 2015

MacLeod N, Chalmers A, O'Rourke N, Moore K, Sheridan J, McMahon L, et al. Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial. Journal of Thoracic Oncology 2015;10(6):944‐50.

Manegold 2003

Manegold C. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Seminars in Oncology 2003;30(4 Suppl 10):32‐6.

Mohamed 2017

Mohamed H, Eltobgy M, Abdel‐Rahman O. Immune checkpoints aberrations and malignant mesothelioma: Assessment of prognostic value and evaluation of therapeutic potentials. Anticancer Agents in Medicinal Chemistry 2017 Jan 2 [Epub ahead of print].

Moher 2009

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.

Mott 2012

Mott FE. Mesothelioma: a review. The Ochsner Journal 2012;12(1):70‐9.

Pruefer 2008

Pruefer FG, Lizarraga F, Maldonado V, Melendez‐Zajgla J. Participation of Omi Htra2 serine‐protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. Journal of Chemotherapy 2008;20(3):348‐54.

RevMan 2014 [Computer program]

Copenhagen: The Nordic Cochrane Centre,The Cochrane Collaboration. Review Manager (RevMan).Version 5.3. Copenhagen: The Nordic Cochrane Centre,The Cochrane Collaboration, 2014.

Robinson 2012

Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Annals of Cardiothoracic Surgery2012; Vol. 1, issue 4:491‐6.

Runxiao 2016

Runxiao L, Yankun C, Lan W. A pilot study of volumetric‐modulated arc therapy for malignant pleural mesothelioma. Journal of Applied Clinical Medical Physics 2016;17(2):5980.

Rusch 2001

Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high‐dose hemithoracic radiation for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular surgery2001; Vol. 122, issue 4:788‐95.

Rusch 2016

Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology 2016;11(12):2112‐9.

Saini 2016

Saini R, Lee NV, Liu KY, Poh CF. Prospects in the application of photodynamic therapy in oral cancer and premalignant lesions. Cancers 2016;8(9):83‐6.

Scherpereel 2010

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal 2010;35(3):479‐95.

Stahel 2015

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncology 2015;16(16):1651‐8.

Sugarbaker 1999

Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long‐term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. Journal of Thoracic and Cardiovascular Surgery 1999;117(1):54‐63; 63‐5.

Testa 2011

Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics 2011;43(10):1022‐5.

Treasure 2011

Treasure T, Lang‐Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. MARS Trialists. Extra‐pleural pneumonectomy versus no extra‐pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncology 2011;12(8):763‐72.

Van Meerbeeck 2011

Van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Critical reviews in Hematology/Oncology2011; Vol. 78, issue 2:92‐111.

Van Schil 2010

Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. European Respiratory Journal2010; Vol. 36, issue 6:1362‐9.

Vogelzang 2003

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2003;21(14):2636‐44.

Weder 2012

Weder W, Opitz I. Multimodality therapy for malignant pleural mesothelioma. Annals of Cardiothoracic Surgery 2012;1(4):502‐7.

Wolchok 2013

Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences 2013;1291:1‐13.

Zalcman 2016

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier‐Valette C, Moro‐Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open‐label, phase 3 trial. Lancet 2016;387(10026):1405‐14.